AGLink® ADC Conjugation Kit (MMAE, DAR2&4, 5mg)

AGLink® ADC Conjugation Kit (MMAE, DAR2&4, 5mg)

• Background: Antibody-drug conjugates (ADC) is a type of fast growing anticancer drug. Monoclonal antibody is conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. AGLink® ADC conjugation kit is designed to conjugate mAb with toxic payload (MMAE) though site-specific enzymatic reaction.
• Description: Antibody-drug conjugates (ADC) is a type of fast growing anticancer drug. Monoclonal antibody is conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. AGLink® ADC conjugation kit is designed to conjugate mAb with toxic payload (MMAE) though site-specific enzymatic reaction.
• Target: MMAE
• Applications: AGLink® ADC Conjugation Kit (MMAE, DAR2&4, 5mg) is designed to conjugate 5mg mAb with toxic payload (MMAE) through site-specific enzymatic reaction.
• Stability: BoxA: The unopened kit is stable for 12 months from the date of manufacture if stored under temperature ≤ -20°C. The opened kit should be stored according to components table. BoxB: The unopened kit is stable for 12 months from the date of manufacture if stored under 4°C. The opened kit should be stored according to components table.
• Format: Solid
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C